Literature DB >> 19828174

Refractory remodeling of the microenvironment by abnormal type V collagen, apoptosis, and immune response in non-small cell lung cancer.

Paola Souza1, Fabrizio Rizzardi, Gustavo Noleto, Marcelo Atanazio, Osmar Bianchi, Edwin Roger Parra, Walcy Rosolia Teodoro, Solange Carrasco, Ana Paula Pereira Velosa, Sandra Fernezlian, Alexandre Muxfeldt Ab'saber, Leila Antonângelo, Tereza Takagaki, Cláudia Goldenstein Schainberg, Natalino Hajime Yoshinari, Vera Luiza Capelozzi.   

Abstract

Collagen V shows promise as an inducer of the death response via caspases. Remodeling of the microenvironment by collagen V, tumoral/vascular apoptosis, and the immune response were evaluated, based on the prognosis of 65 patients with surgically excised non-small cell lung cancer. Immunofluorescence, immunohistochemistry, morphometry, tridimensional reconstruction, and a real-time polymerase chain reaction were used to evaluate the amount, structure, and molecular chains of collagen V, tumoral and vascular apoptosis, immune cells, and microvessel density. The impact of these markers was tested on follow-up until death from recurrent lung cancer occurred. A decreased and abnormal synthesis of collagen V was found to lead to increased angiogenesis due to a low endothelial death rate and a low immune response. A Cox model analysis, controlled for the lymph node stage, demonstrated that only collagen V and vascular apoptosis variables were significantly associated with survival time. A point at the median for collagen V and vascular apoptosis divided patients into 2 groups, each with a distinctive prognosis. Those with a collagen V higher than 9.40% and vascular apoptosis higher than 1.09% had a low risk of death (0.27 and 0.41, respectively) compared to those with a collagen V lower than 9.40% and vascular apoptosis lower than 1.09%. Collagen V and vascular apoptosis in resected non-small cell lung cancer was strongly related to the prognosis, suggesting that strategies aimed at preventing low collagen V synthesis, or local responses to low vascular apoptosis may have a greater impact in lung cancer treatment. Copyright 2010 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19828174     DOI: 10.1016/j.humpath.2009.07.018

Source DB:  PubMed          Journal:  Hum Pathol        ISSN: 0046-8177            Impact factor:   3.466


  12 in total

1.  The new identified biomarkers determine sensitivity to immune check-point blockade therapies in melanoma.

Authors:  Hao Chen; Meng Yang; Qinghua Wang; Fengju Song; Xiangchun Li; Kexin Chen
Journal:  Oncoimmunology       Date:  2019-05-10       Impact factor: 8.110

2.  Id-1, Id-2, and Id-3 co-expression correlates with prognosis in stage I and II lung adenocarcinoma patients treated with surgery and adjuvant chemotherapy.

Authors:  Leila Antonângelo; Taila Tuma; Alexandre Fabro; Milena Acencio; Ricardo Terra; Edwin Parra; Francisco Vargas; Teresa Takagaki; Vera Capelozzi
Journal:  Exp Biol Med (Maywood)       Date:  2016-02-10

3.  Adipose-derived stem cells and adipose-derived stem cell-conditioned medium modulate in situ imbalance between collagen I- and collagen V-mediated IL-17 immune response recovering bleomycin pulmonary fibrosis.

Authors:  Renato Gonçalves Felix; Ana Livia Carvalho Bovolato; Ondina Silvia Cotrim; Patricia Dos Santos Leão; Sabrina Setembre Batah; Márjorie de Assis Golim; Ana Paula Velosa; Walcy Teodoro; Vanessa Martins; Fernanda Ferreira Cruz; Elenice Deffune; Alexandre Todorovic Fabro; Vera Luiza Capelozzi
Journal:  Histol Histopathol       Date:  2019-07-18       Impact factor: 2.303

4.  Does the extent of lymph nodes dissection affect the prognosis of resected stage IA non-small cell lung cancer?

Authors:  F Xu; C Wang; L Qi; W Yu; Q Li
Journal:  Clin Transl Oncol       Date:  2013-04-25       Impact factor: 3.405

5.  Tissue hyaluronan expression, as reflected in the sputum of lung cancer patients, is an indicator of malignancy.

Authors:  M P Rangel; V K de Sá; V Martins; J R M Martins; E R Parra; A Mendes; P C Andrade; R M Reis; A Longatto-Filho; C Z Oliveira; T Takagaki; D M Carraro; H B Nader; V L Capelozzi
Journal:  Braz J Med Biol Res       Date:  2015-05-08       Impact factor: 2.590

6.  Mesenchymal stem cell-derived CXCL16 promotes progression of gastric cancer cells by STAT3-mediated expression of Ror1.

Authors:  Taro Ikeda; Michiru Nishita; Kyoka Hoshi; Takashi Honda; Yoshihiro Kakeji; Yasuhiro Minami
Journal:  Cancer Sci       Date:  2020-02-25       Impact factor: 6.716

7.  An integrative histopathologic clustering model based on immuno-matrix elements to predict the risk of death in malignant mesothelioma.

Authors:  Marcelo Luiz Balancin; Walcy Rosolia Teodoro; Cecilia Farhat; Tomas Jurandir de Miranda; Aline Kawassaki Assato; Neila Aparecida de Souza Silva; Ana Paula Velosa; Roberto Falzoni; Alexandre Muxfeldt Ab'Saber; Anja C Roden; Vera Luiza Capelozzi
Journal:  Cancer Med       Date:  2020-05-11       Impact factor: 4.452

8.  Identification of an Immune Signature Predicting Prognosis Risk and Lymphocyte Infiltration in Colon Cancer.

Authors:  Xinyu Li; Dacheng Wen; Xiaokang Li; Chunli Yao; Wei Chong; Hao Chen
Journal:  Front Immunol       Date:  2020-09-03       Impact factor: 7.561

9.  Tumor⁻Stroma Cross-Talk in Human Pancreatic Ductal Adenocarcinoma: A Focus on the Effect of the Extracellular Matrix on Tumor Cell Phenotype and Invasive Potential.

Authors:  Patrizia Procacci; Claudia Moscheni; Patrizia Sartori; Michele Sommariva; Nicoletta Gagliano
Journal:  Cells       Date:  2018-10-05       Impact factor: 6.600

Review 10.  The role of collagen in cancer: from bench to bedside.

Authors:  Shuaishuai Xu; Huaxiang Xu; Wenquan Wang; Shuo Li; Hao Li; Tianjiao Li; Wuhu Zhang; Xianjun Yu; Liang Liu
Journal:  J Transl Med       Date:  2019-09-14       Impact factor: 5.531

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.